Article
FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Clinical lymphoma, myeloma & leukemia - 1 Oct 2016
Hassanein Mona, Almahayni Muhamad H, Ahmed Syed O, Gaballa Sameh, El Fakih Riad
Abstract excerpt
FLT3 (Fms-like tyrosine kinase 3) inhibitors are tyrosine kinase inhibitors. The first-generation FLT3 inhibitors were developed several years ago and include midostaurin, lestaurtinib, sunitinib, and sorafenib. They are relatively nonspecific for FLT3, with other potential targets that include platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and Janus kinase 2. The...
Topics
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Trials as Topic
- Drug Resistance, Neoplasm
- Gene Duplication
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors